Aerocrine wins patent infringement suit against Medisoft in Germany

Aerocrine wins patent infringement suit against Medisoft in Germany 

SOLNA, Sweden - 24 September 2009 - Aerocrine AB today announced the positive
outcome of its complaint against Medisoft P.A.E. filed at the District Court of
Dusseldorf, Germany.

In March 2008, Aerocrine sued the Belgian company Medisoft for patent
infringement before the District Court of Düsseldorf. Yesterday the District
Court announced its written decisions that the Medisoft device Hyp'Air FeNO
infringes Aerocrine's patents EP 0 606 351 B1, EP 1 439 781 B1 and EP 0 724 723
B1. The judgments may be appealed by Medisoft and Medisoft has announced to file
invalidity proceedings against Aerocrines patents. 

“We are pleased that the Dusseldorf District Court has confirmed our view that
Medisoft is infringing several Aerocrine patents in Germany”, says Paul de
Potocki, CEO of Aerocrine AB. “Should Medisoft proceed to an invalidity process,
we firmly believe that our patents are valid and that this will be confirmed by
the German Federal Patents Court”.

For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 80

About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management
and care of patients with inflammatory airway diseases. The pioneer and leader
in the technology to monitor and manage airway inflammation, Aerocrine markets
NIOX MINO® and NIOX® Flex. Both products enable the fast and reliable
measurement of airway inflammation and may thus play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm
Stock Exchange on 15 June 2007.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act. The information was submitted for publication at
12:00 am on September the 24th 2009.